{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:00:10Z","timestamp":1794344410518,"version":"4.9.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011495","name":"Massachusetts Life Sciences Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011495","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.metabol.2023.155694","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T17:04:58Z","timestamp":1695661498000},"page":"155694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study"],"prefix":"10.1016","volume":"148","author":[{"given":"Laura","family":"Valenzuela-Vallejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlina","family":"Chrysafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matina","family":"Kouvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guatibonza-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia C.","family":"Mylonakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeliki","family":"Katsarou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Verrastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Markakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Eslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Papatheodoridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geltrude","family":"Mingrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2023.155694_bb0005","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2023.155694_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154822","article-title":"Preparing for the NASH epidemic: a call to action","volume":"122","author":"Kanwal","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2023.155694_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155664","article-title":"From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need","volume":"147","author":"Kokkorakis","year":"2023","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2023.155694_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154318","article-title":"Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)","volume":"111","author":"Polyzos","year":"2020","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2023.155694_bb0025","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2023.155694_bb0030","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000443344","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"9","author":"European Association for the Study of the Liver (EASL)","year":"2016","journal-title":"Obes Facts"},{"key":"10.1016\/j.metabol.2023.155694_bb0035","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2023.155694_bb0040","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2023.155694_bb0045","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.metabol.2023.155694_bb0050","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jhep.2022.11.029","article-title":"Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease","volume":"78","author":"Sanyal","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2023.155694_bb0055","first-page":"1319","article-title":"Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors","volume":"79","author":"Muzurovi\u0107","year":"2022","journal-title":"Hypertens Dallas Tex 1979"},{"key":"10.1016\/j.metabol.2023.155694_bb0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.09.026","article-title":"ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD","volume":"76","author":"Corey","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2023.155694_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154770","article-title":"Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk","volume":"119","author":"Muzurovi\u0107","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2023.155694_bb0070","doi-asserted-by":"crossref","first-page":"155246","DOI":"10.1016\/j.metabol.2022.155246","article-title":"Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD)","volume":"134","author":"Valenzuela-Vallejo","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2023.155694_bb0075","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3390\/jpm13050830","article-title":"Precision medicine in fatty liver disease\/non-alcoholic fatty liver disease","volume":"13","author":"Valenzuela-Vallejo","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.metabol.2023.155694_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155676","article-title":"Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease","volume":"147","author":"Polyzos","year":"2023","journal-title":"Metab - Clin Exp"},{"key":"10.1016\/j.metabol.2023.155694_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155642","article-title":"Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States","volume":"146","author":"Golabi","year":"2023","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2023.155694_bb0090","doi-asserted-by":"crossref","first-page":"6996","DOI":"10.3390\/ijms23136996","article-title":"Fibrogenic pathways in metabolic dysfunction associated fatty liver disease (MAFLD)","volume":"23","author":"Subramanian","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2023.155694_bb0095","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2147\/DMSO.S292926","article-title":"Association between metabolic associated fatty liver disease and chronic kidney disease: a cross-sectional study from NHANES 2017-2018","volume":"14","author":"Deng","year":"2021","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"10.1016\/j.metabol.2023.155694_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2022.101369","article-title":"Liraglutide-induced effects on energy intake and glycemic profile are independent of total and intact GDF-15 levels in subjects with obesity and diabetes","volume":"48","author":"Valenzuela-Vallejo","year":"2022","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.metabol.2023.155694_bb0105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cmet.2018.07.018","article-title":"The MIC-1\/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases","volume":"28","author":"Tsai","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2023.155694_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155237","article-title":"Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity","volume":"133","author":"Valenzuela-Vallejo","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2023.155694_bb0115","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/jalm\/jfac055","article-title":"The common H202D variant in GDF-15 does not affect its bioactivity but can significantly interfere with measurement of its circulating levels","volume":"7","author":"Karusheva","year":"2022","journal-title":"J Appl Lab Med"},{"key":"10.1016\/j.metabol.2023.155694_bb0120","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/jnci\/djh227","article-title":"H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer","volume":"96","author":"Lindmark","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.metabol.2023.155694_bb0125","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev-physiol-022020-045449","article-title":"The GDF15-GFRAL pathway in health and metabolic disease: friend or foe?","volume":"83","author":"Breit","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.metabol.2023.155694_bb0130","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","article-title":"Bariatric\u2013metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial","volume":"401","author":"Verrastro","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.metabol.2023.155694_bb0135","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/MCG.0b013e3181dd1348","article-title":"Generalizability of the NASH CRN histological scoring system for nonalcoholic fatty liver disease","volume":"45","author":"Juluri","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.metabol.2023.155694_bb0140","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.metabol.2023.155694_bb0145","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.21037\/qims-21-895","article-title":"Ultrasonographic index for the diagnosis of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease","volume":"12","author":"Kim","year":"2022","journal-title":"Quant Imaging Med Surg"},{"key":"10.1016\/j.metabol.2023.155694_bb0150","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","author":"Davison","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2023.155694_bb0155","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1210\/jc.2018-01056","article-title":"Physiology of activins\/follistatins: associations with metabolic and anthropometric variables and response to exercise","volume":"103","author":"Perakakis","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2023.155694_bb0160","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s00125-010-1869-7","article-title":"Day\/night variations of high-molecular-weight adiponectin and lipocalin-2 in healthy men studied under fed and fasted conditions","volume":"53","author":"Scheer","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2023.155694_bb0165","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12967-019-2060-7","article-title":"Plasma concentration and expression of adipokines in epicardial and subcutaneous adipose tissue are associated with impaired left ventricular filling pattern","volume":"17","author":"Toczylowski","year":"2019","journal-title":"J Transl Med"},{"key":"10.1016\/j.metabol.2023.155694_bb0170","doi-asserted-by":"crossref","first-page":"e520","DOI":"10.1210\/clinem\/dgaa792","article-title":"Relationship of IGF-1 and IGF-binding proteins to disease severity and Glycemia in nonalcoholic fatty liver disease","volume":"106","author":"Stanley","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2023.155694_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155589","article-title":"Direct and systemic actions of growth hormone receptor (GHR)-signaling on hepatic glycolysis, de novo lipogenesis and insulin sensitivity, associated with steatosis","volume":"144","author":"V\u00e1zquez-Borrego","year":"2023","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2023.155694_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.683250","article-title":"Adiponectin, leptin, and IGF-1 are useful diagnostic and stratification biomarkers of NAFLD","volume":"8","author":"Marques","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.metabol.2023.155694_bb0185","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142245","article-title":"Severe insulin resistance syndromes","volume":"131","author":"Angelidi","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2023.155694_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.154026","article-title":"Low levels of total and high-molecular-weight adiponectin may predict non-alcoholic fatty liver in Korean adults","volume":"103","author":"Kim","year":"2020","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2023.155694_bb0195","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000112","article-title":"Clustering NAFLD: phenotypes of nonalcoholic fatty liver disease and their differing trajectories","volume":"7","author":"Kantartzis","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.metabol.2023.155694_bb0200","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1021\/acs.analchem.7b05215","article-title":"Spatial systems lipidomics reveals nonalcoholic fatty liver disease heterogeneity","volume":"90","author":"\u0160\u010dup\u00e1kov\u00e1","year":"2018","journal-title":"Anal Chem"},{"key":"10.1016\/j.metabol.2023.155694_bb0205","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnaa007","article-title":"GDF15: a hormone conveying somatic distress to the brain","volume":"41","author":"Lockhart","year":"2020","journal-title":"Endocr Rev"},{"key":"10.1016\/j.metabol.2023.155694_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101117","article-title":"Growth differentiation factor 15 as a potential therapeutic for treating obesity","volume":"46","author":"Hale","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2023.155694_bb0215","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41387-022-00187-2","article-title":"Growth differentiation factor 15 (GDF15) is associated with non-alcoholic fatty liver disease (NAFLD) in youth with overweight or obesity","volume":"12","author":"Galuppo","year":"2022","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.metabol.2023.155694_bb0220","first-page":"695","article-title":"Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease","volume":"38","author":"Koo","year":"2018","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.metabol.2023.155694_bb0225","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.cell.2019.07.033","article-title":"GDF15 is an inflammation-induced central mediator of tissue tolerance","volume":"178","author":"Luan","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2023.155694_bb0230","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.bbrc.2018.04.061","article-title":"CST3 and GDF15 ameliorate renal fibrosis by inhibiting fibroblast growth and activation","volume":"500","author":"Kim","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2023.155694_bb0235","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.bbrc.2017.08.096","article-title":"Hepatic GDF15 is regulated by CHOP of the unfolded protein response and alleviates NAFLD progression in obese mice","volume":"498","author":"Li","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2023.155694_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102322","article-title":"Overexpression of NAG-1\/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation","volume":"52","author":"Wang","year":"2022","journal-title":"Redox Biol"},{"key":"10.1016\/j.metabol.2023.155694_bb0245","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1210\/en.2012-1844","article-title":"Increased activin bioavailability enhances hepatic insulin sensitivity while inducing hepatic steatosis in male mice","volume":"154","author":"Ungerleider","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2023.155694_bb0250","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.metabol.2016.07.009","article-title":"Activin a and follistatin in patients with nonalcoholic fatty liver disease","volume":"65","author":"Polyzos","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2023.155694_bb0255","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1210\/clinem\/dgz172","article-title":"Targeted analysis of three hormonal systems identifies molecules associated with the presence and severity of NAFLD","volume":"105","author":"Polyzos","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2023.155694_bb0260","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1038\/ajg.2009.318","article-title":"A complex role of activin a in non-alcoholic fatty liver disease","volume":"104","author":"Yndestad","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.metabol.2023.155694_bb0265","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.2147\/DMSO.S380053","article-title":"Follistatin alleviates hepatic steatosis in NAFLD via the mTOR dependent pathway","volume":"15","author":"Tong","year":"2022","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"10.1016\/j.metabol.2023.155694_bb0270","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1590\/1414-431X20143869","article-title":"Effect of physical training on liver expression of activin a and follistatin in a nonalcoholic fatty liver disease model in rats","volume":"47","author":"Silva","year":"2014","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.metabol.2023.155694_bb0275","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.bbadis.2017.12.031","article-title":"Activin-a causes hepatic stellate cell activation via the induction of TNF\u03b1 and TGF\u03b2 in Kupffer cells","volume":"1864","author":"Kiagiadaki","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.metabol.2023.155694_bb0280","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1507\/endocrj.EJ12-0322","article-title":"Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver","volume":"59","author":"Takahashi","year":"2012","journal-title":"Endocr J"},{"key":"10.1016\/j.metabol.2023.155694_bb0285","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1530\/EJE-12-0252","article-title":"Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy","volume":"167","author":"Nishizawa","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2023.155694_bb0290","doi-asserted-by":"crossref","first-page":"19937","DOI":"10.1074\/jbc.M109.014308","article-title":"Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism","volume":"284","author":"Fan","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2023.155694_bb0295","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/MED.0000000000000184","article-title":"Leptin applications in 2015: what have we learned about leptin and obesity?","volume":"22","author":"Farr","year":"2015","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.metabol.2023.155694_bb0300","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s001250050838","article-title":"Leptin: its role in obesity and beyond","volume":"40","author":"Tritos","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2023.155694_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.154028","article-title":"Adiponectin and leptin in the diagnosis and therapy of NAFLD","volume":"103","author":"Boutari","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2023.155694_bb0310","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s00125-012-2598-x","article-title":"Adiponectin: mechanistic insights and clinical implications","volume":"55","author":"Turer","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2023.155694_bb0315","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.metabol.2014.10.012","article-title":"Leptin in nonalcoholic fatty liver disease: a narrative review","volume":"64","author":"Polyzos","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2023.155694_bb0320","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.metabol.2019.05.001","article-title":"Fatty liver in lipodystrophy: a review with a focus on therapeutic perspectives of adiponectin and\/or leptin replacement","volume":"96","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2023.155694_bb0325","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.2337\/diacare.26.8.2442","article-title":"Adiponectin: more than just another fat cell hormone?","volume":"26","author":"Chandran","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2023.155694_bb0330","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/liv.15005","article-title":"PPAR-\u03b3-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH","volume":"41","author":"Gastaldelli","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2023.155694_bb0335","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3803\/EnM.2018.33.1.33","article-title":"Association of adipokines with development and progression of nonalcoholic fatty liver disease","volume":"33","author":"Boutari","year":"2018","journal-title":"Endocrinol Metab Seoul Korea"},{"key":"10.1016\/j.metabol.2023.155694_bb0340","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.metabol.2010.09.003","article-title":"Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"60","author":"Polyzos","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2023.155694_bb1000","doi-asserted-by":"crossref","first-page":"155666","DOI":"10.1016\/j.metabol.2023.155666","article-title":"Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study","volume":"147","author":"Kouvari","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2023.155694_bb1005","doi-asserted-by":"crossref","first-page":"110870","DOI":"10.1016\/j.diabres.2023.110870","article-title":"The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter study","volume":"203","author":"Kouvari","year":"2023","journal-title":"Diabetes Res. Clin. Pract."}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049523002986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049523002986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:34:14Z","timestamp":1758429254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049523002986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":70,"alternative-id":["S0026049523002986"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2023.155694","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2023.155694","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155694"}}